Wealthquest Corp Invests $56,000 in Elanco Animal Health Incorporated (NYSE:ELAN)

Wealthquest Corp bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,377 shares of the company’s stock, valued at approximately $56,000.

A number of other large investors have also modified their holdings of the stock. Steward Partners Investment Advisory LLC raised its stake in shares of Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock valued at $124,000 after purchasing an additional 2,264 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Elanco Animal Health by 6.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock valued at $216,774,000 after purchasing an additional 1,074,274 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. Yousif Capital Management LLC acquired a new position in shares of Elanco Animal Health in the first quarter worth about $119,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Elanco Animal Health by 9.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,611 shares of the company’s stock worth $1,424,000 after acquiring an additional 9,928 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of several recent analyst reports. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, May 19th. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $15.17.

Elanco Animal Health Stock Up 1.9%

NYSE:ELAN opened at $13.77 on Thursday. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68. The stock has a 50 day moving average of $12.15 and a 200-day moving average of $11.49. The firm has a market capitalization of $6.84 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 2.65 and a beta of 1.67. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.09.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the firm posted $0.34 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. Analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.